4//SEC Filing
Doyle John Brendan 4
Accession 0001209191-21-050010
CIK 0001339469other
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 5:26 PM ET
Size
6.9 KB
Accession
0001209191-21-050010
Insider Transaction Report
Form 4
CHIASMA, INCCHMA
Doyle John Brendan
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-08-05−175,000→ 0 totalExercise: $3.95→ Common Stock (175,000 underlying)
Footnotes (2)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").
- [F2]At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Documents
Issuer
CHIASMA, INC
CIK 0001339469
Entity typeother
Related Parties
1- filerCIK 0001840738
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 5:26 PM ET
- Size
- 6.9 KB